Healthcare
Novo Nordisk India head eyes 2026 launch for obesity drug Wegovy, warns against copycats
Novo Nordisk plans to bring its weight-loss drug, Wegovy, to India in 2026. The company aims to secure regulatory approvals and ensure sufficient supply before entering the Indian market, where obesity rates are high. Counterfeit versions of Wegovy are already being sold online, but Novo Nordisk urges patients not to buy them due to safety concerns.
Dengue causing blood pressure, heart rate changes
In India, dengue infection is spreading rapidly in Delhi, West Bengal, Maharashtra and Jharkhand. Mumbai has reported a significant upsurge in infections, recording 3,068 cases between June and September 25, a threefold increase from the previous year.
Weight loss drinks: Vegetable juices to shed belly fat quickly
This low-calorie root vegetable is high in fibre and aids digestion, all of which contribute to weight loss.
WHO South-East Asia Region calls on member states to raise awareness about heart health
The main causes to the burden of cardiovascular diseases include modifiable lifestyle factors such as tobacco use, alcohol consumption, unhealthy diets -- especially high salt intake -- and lack of physical activity. Raised blood pressure and glucose levels are the key drivers and these can be detected, diagnosed and managed adequately in primary care, she added.
Norwest set to buy 40% in Regency Health for '600 cr
International Finance Corporation (IFC) and HealthQuad invested around $14 million in Regency Healthcare in 2016. Both will exit as part of the arrangement. Atul Kapoor, Norwest Venture, IFC and HealthQuad did not respond to ET's requests for comment.
About 70 per cent of premature cancer deaths in 2020 preventable, 30 per cent treatable: Lancet study
The IARC conducts and coordinates research into the causes of cancer and is an intergovernmental agency under the World Health Organization of the United Nations. Tobacco, alcohol, obesity, and infections accounted for roughly 1.3 million deaths in women across all age groups in 2020, the study reported, acknowledging that the burden of cancer in women due to these risk factors was widely under-recognised.
Apollo acquires under-development hospital asset from Future Oncology in Kolkata for Rs 102 crore
Apollo Hospitals has acquired a partially built hospital in Sonarpur, Kolkata with a total capacity of 325 beds. The acquisition, worth Rs 102 crore, is being fully funded by Apollo Multi Speciality Hospitals. The hospital will offer high-end specialties including comprehensive oncology services with radiotherapy. This acquisition strengthens Apollo's position as the largest healthcare provider in the eastern region, with over 1800 beds across Kolkata, Bhubaneshwar, and Guwahati.
CVC may sell controlling stake in Indian hospital chain HealthCare Global
Private equity firm CVC Capital Partners is reportedly considering selling its 60.4% stake in Indian cancer hospital chain HealthCare Global Enterprises Ltd. The stake is valued at around $358 million. CVC may seek a premium of at least 20% for the shares, potentially even up to 50%, depending on market conditions. The rising demand for private medical services in Asia has increased deal activity in the healthcare sector. HealthCare Global owns 24 cancer centers across India and serves over 200,000 patients annually.
Sparsh group of hospitals to create 1600 jobs over two years
The Sparsh group has five hospitals as of now, with three in Bengaluru and one each in Hassan and Davangere. While expansion is underway, there are no plans of opening hospitals in tier 2 and 3 cities in the next few years, said Dr. Patil. “The challenge in these towns is getting skilled professionals to set up base and work there. Infrastructure is another huge drawback, as is the lack of equipment,” he said.
ICMR worried over rising resistance to last-resort antibiotics in India
ICMR has found the abuse of antimicrobials (antibiotics, antivirals or antifungals) to be the reason for this, which is says has led to widespread resistance among people.
CCI approves Blackstone, TPG stake buy in Quality Care India
According to two separate releases, CCI said it has approved the acquisition of about 72.49 per cent and 24.16 per cent stake in Quality Care India Ltd by BCP Asia II and Centella Mauritius Holdings Ltd, respectively. BCP Asia II is controlled by funds advised and/or managed by affiliates of Blackstone Inc, while Centella Mauritius Holdings is a special purpose investment vehicle controlled by the affiliates of TPG Inc.
Must Watch
ICMR permits Kerala to conduct Truenat portable tests in boost for state's Nipah containment response
With Truenat available locally, only samples that test positive for Nipah need be sent to Thiruvananthapuram, Thonnakkal, or Kozhikode labs for reconfirmation. This will help Kerala conduct tests faster, detect if there is an outbreak, and set preventive measures faster, she told reporters.
Manipal completes Kolkata's AMRI Hospitals acquisition
Manipal Hospitals, the second-largest hospital chain in India, has completed the acquisition of an 84% stake in AMRI Hospitals Ltd. The acquisition is part of Manipal Hospitals' strategy to expand its footprint in eastern India and strengthen its presence. The deal, worth Rs 2,400 crore, was finalized after prolonged negotiations and court battles.
Demand for healthcare products returns as Covid base effect normalises
"We are seeing steady recovery in our healthcare portfolio, which is a higher margin business. We expect healthcare alone to be a ₹5,000 crore business in the near term," Dabur India CEO Mohit Malhotra said while addressing investors. The company's healthcare portfolio includes Chyawanprash, Honitus and Honey. In FY23, Dabur's healthcare business clocked revenue of ₹2,581 crore, more than the ₹1,724 crore in its food and beverage business.
Danaher cuts TB diagnosis test cartridge by 20% for high-burden countries
Danaher Corporation announced that it will reduce the price of its Cepheid's Xpert MTB/RIF Ultra diagnostic test cartridges for tuberculosis by 20% in high-TB-burden countries. The price will be decreased from $9.98 to $7.97 per test to support greater access to high-quality TB testing.
'New Covid variant Pirola not yet detected in India'
The Indian SARS-CoV-2 Genomics Consortium (Insacog) held a meeting on Friday to review the Covid situation and has not found anything "unusual", a member of the network said.
